Tag/Conjugate
Unconjugated
Bio-activity
Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt‑1 Fc Chimera is immobilized at 0.5 μg/mL, 100 μL/well, the concentration of Recombinant Human PlGF that produces 50% of the optimal binding response is approximately 0.15-0.9 ng/mL.
Alternative Names
D12S1900; PGF; PGFL; placenta growth factor; placental growth factor; placental growth factor, vascular endothelial growth factor-related protein; PlGF; PlGF-2; PLGFplacental growth factor-like; SHGC-10760
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Concentration
Batch dependent - please inquire should you have specific requirements.
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 3 months, -20 to -70°C under sterile conditions after Reconstitution.
Reconstitution
Reconstitute at 200 μg/mL in 4 mM HCl.
Antigen Description
Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternative splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. Human PlGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PlGF, respectively. PlGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1 but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, but not PLGF-1, shows heparin-dependent binding of Neuropilin (Npn)-1 and Npn-2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis. PlGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension.
Keywords
D12S1900;PGF;PGFL;placenta growth factor;placental growth factor;placental growth factor, vascular endothelial growth factor-related protein;PlGF;PlGF-2; PLGFplacental growth factor-like;SHGC-10760
Citations
Publication ()
Have you cited DAG-PG01 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
